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AbstrACt
Objective Participation rates in clinical trials are low in 
teenagers and young adults (TYA) with cancer. Whilst the 
importance of clinical trials in informing best practice is 
well established, data regarding individual patient benefit 
are scarce. We have investigated the association between 
overall survival and trial recruitment in TYA patients with 
acute lymphoblastic leukaemia (ALL).
Design Retrospective.
setting National (England) TYA patients treated for ALL.
Participants 511 patients aged 15–24 years diagnosed 
with ALL between 2004 and 2010 inclusive, of whom 239 
(46.7%) participated in the UKALL2003 trial.
Outcome measures Patients were identified using 
National Clinical Trial (UKALL2003) and Cancer Registry 
(National Cancer Data Repository, English National 
Cancer Online Registration Environment) Databases. 
Relative survival rates were calculated for trial and non-
trial patients and observed differences were modelled 
using a multiple regression approach. The numbers and 
percentages of deaths in those patients included in the 
survival analysis were determined for each 3-month 
period, p values were calculated using the two-tailed 
z-test for difference between proportions and 95% CIs 
for percentage deaths were derived using the binomial 
distribution based on the Wilson Score method.
results Patients treated on the trial had a 17.9% better 
2-year survival (85.4% vs 67.5%, p<0.001) and 8.9% 
better 1-year survival (90.8% vs 81.9%, p=0.004) than 
those not on the trial. 35 (14.6%) patients recruited to the 
trial died in the 2 years following diagnosis compared with 
86 (32.6%) of those not recruited (p<0.001).
Conclusions TYA patients recruited to the clinical trial 
UKALL 2003 in England had a lower risk of mortality and 
a higher overall survival than contemporaneous non-trial 
patients. These data underline the potential for individual 
patient benefit in participating in a clinical trial and 
the importance of international efforts to increase trial 
participation in the TYA age group.
trial registration number ISRCTN07355119.
IntrODuCtIOn
Although survival rates in teenage and 
young adult (TYA) patients with cancer have 
improved over the last two decades,1 these 
outcome gains have been modest and cancer 
remains the leading cause of non-accidental 
mortality in the TYA age group.2 3
The barriers to improving survival are likely 
to be multifactorial and include suboptimal 
diagnostic pathways, complex tumour and 
host biology, access to age or site-specific 
specialist care and poor compliance with 
treatment.4 5 Importantly, recruitment rates 
strengths and limitations of this study
 ► The study asks a fundamental question regarding 
the value to an individual of recruitment to a clinical 
trial.
 ► Large sample size including all TYA patients aged 
15–24 years diagnosed with ALL in England 
between 2004 and 2010.
 ► This retrospective study is possible because (1) the 
consent process for UKALL2003 included explicit 
consent for the trial data to be shared with regional 
and national cancer registries and (2) because the UK 
has full population coverage for cancer registration.
 ► Clinically, significant outcomes of survival and 
mortality in those recruited to the clinical trial, 
UKALL2003, are compared with contemporaneous 
patients treated off trial.
 ► Given the retrospective design of this study, there is 
an inherent risk of potential confounding variables 
influencing the observations, which are fully 
explored in the discussion; these include selection 
bias, centre effect, protocol used and recruitment to 
other clinical trials.
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to clinical trials in TYA patients with cancer are the lowest 
of any age group.5–8 In those patients for whom clin-
ical trials are available, factors influencing participation 
include whether the treating physician is from a paedi-
atric or adult background,5 9–12 the type of treating centre 
(academic, tertiary or other)9 and patient factors, notably 
the acceptability to and attitudes of TYA patients.13 In 
addition, there are often fewer clinical trials available 
to TYA patients than to younger or older patients with 
cancer,7 8 14 reflecting the unique distribution of tumours 
in this age group and the traditional separation between 
adult and paediatric clinical research programmes.5
While sequential clinical trials clearly inform evidence-
based best practice in cancer therapy and have improved 
outcomes in specific disease types,15 the value of partici-
pation for an individual patient is less clear. The benefits 
may include access to a superior therapy not otherwise 
available, enhanced quality of care, access to a broader 
team of specialised professionals16 and stricter adherence 
to trial mandated treatment. However, to date, no study 
has demonstrated a survival advantage specifically associ-
ated with trial participation in TYA patients.17 18
The objective of this study was to report survival 
outcomes of TYA patients with acute lymphoblastic 
leukaemia (ALL) in England who were treated within or 
outside of the national clinical trial, UKALL2003.
MethODs
uKALL2003
UKALL2003 was the UK clinical trial of minimal residual 
disease (MRD)-directed chemotherapy for Philadel-
phia chromosome negative ALL in children and young 
people aged 1–24 years, which opened in 2003 and closed 
in 2011. The maximum age for trial entry was the 18th 
birthday when the trial began, but was increased to the 
20th birthday in 2006 and the 25th birthday in 2007. 
Details of the protocol and outcomes of the trial have 
been published previously.19–21 The consent form for 
UKALL2003 included explicit consent for data sharing 
with national cancer registries. Patients with Philadel-
phia chromosome positive ALL were eligible for post-in-
duction recruitment to the European intergroup study 
on post-induction treatment of Philadelphia positive 
ALL (ESPHALL) trial if aged less than 18 years (until 
2009) or UKALL XII if aged 18 years or older (until 2006). 
The lower age limit for recruitment of patients with Phil-
adelphia negative ALL to UKALL XII was sequentially 
increased according to the change in the upper age limit 
for UKALL2003 to avoid overlapping age eligibility for the 
two trials. These changes to age eligibility for UKALL2003 
and UKALL XII were communicated in newsletters circu-
lated by the clinical trials unit and presented at both 
paediatric and adult annual national leukaemia trials 
update meetings. The National Institute for Health 
Research also hosts a trial database, which summarised 
all of these trials and was searchable by any clinician. The 
Strengthening the reporting of observational studies in 
epidemiology (STROBE) guidelines for the reporting of 
observational studies was followed.
study population
The study population for this analysis was defined as 
any patient diagnosed with ALL in 2004–2010 (the 
seven complete years during which UKALL2003 was 
recruiting), aged 15–24 years and resident in England 
at the time of diagnosis. The diagnosis reported to 
the registry and trial was made in the laboratories of 
treating centre, without central verification. Details 
were obtained on the 337 TYA patients who took part 
in the UKALL2003 Trial including name, date of birth 
and hospital of treatment, but not address or country 
of residence. Details of missing NHS numbers on 
UKALL2003 were obtained using the NHS Strategic 
Tracing Service (NSTS), which contains details of all 
individuals registered with a GP in England or Wales. 
The National Cancer Data Repository (NCDR) was the 
database used to undertake cancer analyses at the time 
this study commenced. It included details of all patients 
diagnosed with cancer who were resident in England. 
A frozen copy of NCDR was compiled from the eight 
regional registries then in existence, when cancer data 
for a given calendar year were considered to be near 
complete—a process which took considerable time. 
The version used in this study was that produced when 
2010 data were considered complete. The patients in 
UKALL2003 were matched against those on the NCDR 
database who were diagnosed in 2004–2010 aged 15–24 
years with any cancer. Patients recorded on NCDR as 
having ALL and who were not on the UKALL database 
were included in our study as the non-trial arm.
The move to a single cancer registry for England, which 
was completed while this study was underway, resulted in 
the production of the English National Cancer Online 
Registration Environment (ENCORE). This is a live data-
base, which is updated regularly. It is used by registry 
staff to determine if a given patient has already been 
registered. It contains details of all residents of England 
who have been diagnosed with cancer, including patients 
reported to the National Cancer Registration and Anal-
ysis Service (NCRAS) but with insufficient details to be 
counted as a case of cancer; these are called provisional 
registrations and are upgraded to full registrations when 
further details are obtained. ENCORE also contains 
details of patients with cancer managed at a hospital in 
England but resident elsewhere. Patients on the UKALL 
database not found on NCDR were manually checked on 
ENCORE, in order to determine the reasons why these 
patients were not on NCDR and to identify any patients 
reported to NCRAS after the NCDR was compiled. Those 
whose records were found on ENCORE and who fulfilled 
the study definition were added to patients on both 
UKALL and NCDR to make up the trial arm in our study.
Details of patients on the UKALL database but not 
found on ENCORE were checked against the NSTS 
to determine whether living in England or Wales. The 
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UKALL database was interrogated for the country of the 
treating hospital for those patients not found on NSTS.
Consent
Registry data was routinely submitted to the national 
cancer registry under legal permissions that were initially 
included under Section 60 of the Health and Social Care 
Act 2001 and more recently Section 251 of the NHS 
Act 2006. This permission is renewed annually. Identifi-
able trial data were shared with explicit patient consent 
obtained during trial registration.
Analyses
We determined the number and percentage of patients 
who participated in UKALL2003 by year of diagnosis and 
age group. Survival rates were calculated for patients in 
the trial and not in the trial, excluding patients on whom 
the only available data were from death certificates—
death certificate only (DCO) registrations. Death details 
were obtained from NCDR up to the end of 2012, with 
follow-up starting from the date of diagnosis recorded on 
NCDR; the equivalent data were obtained from ENCORE 
for those patients not found on NCDR. One year, 2 year 
and 2 year conditional on 1 year relative survival rates were 
calculated for trial and non-trial patients aged 15–24, 
15–19 and 20–24 years. Relative survival was estimated 
from life tables stratified by age, sex and time using the 
Stata strs programme.22 Expected survival was estimated 
using the Ederer II method.
Differences in relative survival were modelled using a 
multiple regression approach based on generalised linear 
models, assuming a Poisson distribution for the observed 
number of deaths.23 Differences were considered statisti-
cally significant if two-sided p values were <0.05. All statis-
tical analyses were conducted using Stata V.13.
The numbers of deaths in those patients included in 
the survival analysis were determined for each 3-month 
period during the 2 years of follow-up and percentages 
calculated based on the number of patients alive at the 
beginning of each 3-month period. p Values were calcu-
lated using the two-tailed z-test for difference between 
proportions. The 95% CIs for percentage deaths were 
derived using the binomial distribution based on the 
Wilson Score method.24
Completion of tYAC form
During 2009 and 2010, enhanced cancer registration 
forms were in use throughout the English TYA Prin-
cipal Treatment Centres (PTCs). The forms were devel-
oped by the professional organisation Teenagers and 
Young Adults with Cancer (TYAC) (http://www. tyac. org. 
uk) and were collected and matched with registry data 
by the lead UK regional registry for TYA cancer at the 
time, the North West Cancer Intelligence Service (now 
part of Public Health England (PHE)). Receipt of a 
TYAC form by the registry was used as a proxy that the 
patient’s management had been provided by or at least 
discussed with the regional TYA PTC. We calculated the 
percentage of patients in the trial for whom a TYAC form 
was completed to explore the relationship between access 
to TYA specialist services and participation in the trial.
resuLts
study population
The process by which the study population was selected is 
shown in figure 1. Details on 227 of the 337 patients on the 
UKALL database were found on NCDR; 20 of whom had 
a diagnosis other than ALL on NCDR. The most common 
diagnoses were leukaemia (5), acute leukaemia (4), acute 
myeloid leukaemia (4) and non-Hodgkin's lymphoma 
(4). Two hundred and seventy-two patients with a diag-
nosis of ALL on NCDR were not on the UKALL database 
and these constituted the non–trial arm of this study.
Of the 110 patients on UKALL2003 not found on 
NCDR, 43 were identified on ENCORE. Thirty-one did 
not fulfil the study definition for the following reasons:
a. Twenty-six were diagnosed in 2011.
b. One diagnosed in 2003.
c. One aged 14 at time of diagnosis.
d. One treated in England but not a resident.
e. Two were provisional registrations that were not 
confirmed.
The 12 patients who fulfilled the study definition 
had been reported to the NCRAS after the NCDR was 
compiled. These patients were added to the 227 found 
on both the UKALL2003 and NCDR databases to make 
up the trial arm of this study.
Figure 1 Study population derived from matching 
UKALL2003 against the National Cancer Data Repository 
(NCDR) and English National Cancer Online Registration 
Environment (ENCORE).
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Of the 67 patients on the UKALL2003 database not 
found on ENCORE, 60 were not resident in England 
confirmed by having a non-English address on NSTS and/
or the treating hospital recorded on UKALL2003 as being 
outside England. The remaining seven patients, who did 
fulfil the study definition were excluded for a number of 
reasons, including not being reported to the registry by 
the treating hospital or insufficient details provided to 
allow a full registration and inaccurate personal details 
on the UKALL2003 database resulting in patients not 
being found on ENCORE.
Participation in uKALL2003
A total of 511 patients aged 15–24 years were included in 
the analyses, of whom 239 (47.5%) had participated in 
UKALL2003 (table 1a). The overall number of patients 
aged 20–24 years recruited (36 patients) was lower than 
patients aged 18–19 years (54 patients) and 15–17 years 
(149 patients). In total, 203 (84.9%) of 239 trial patients 
were aged 15–19 years. Trial participation improved over 
time, from 59.3% in 2004–2007 to 76.7% in 2008–2010 
(p=0.007) in the group aged 15–17 years (the only group 
eligible for the trial for the entire study period) (table 1b). 
It is likely that the sequential changes in age eligibility 
criteria for UKALL2003 were partly responsible for low 
recruitment numbers in the older age groups. However, 
for the period 2008–2010, during which all 15–24 year 
olds were eligible for the study, participation remained 
higher in younger patients: 76.3% of 15–19 year olds 
compared with 45.1% of 20–24 year olds (p<0.001).
recruitment to other clinical trials
Since the trial consent forms for ESPHALL and UKALLXII 
did not include explicit consent for data sharing with the 
national registries, it was not possible to access detailed 
information from these trial databases. However, the 
overall number of UK patients recruited to these trials 
within the study period included three patients aged 
15–17 years recruited to ESPHALL and 100 patients aged 
15–24 years recruited to UKALL XII. Although ESPHALL 
recruited only those with Philadelphia chromosome posi-
tive disease, UKALL XII recruited both Philadelphia 
chromosome positive and negative patients with ALL. 
Given that the lower age limit for UKALL XII for Phil-
adelphia chromosome negative ALL was sequentially 
increased over time, the highest proportion of patients 
recruited to UKALL XII would be those with Philadelphia 
chromosome negative disease in the older age group.
survival
Five hundred and three patients were included in the 
survival analysis: 239 in the trial arm and 264 in the 
non-trial arm. Patients aged 15–24 years recruited to the 
UKALL2003 trial had 17.9% better 2-year survival (85.4% 
vs 67.5%, p<0.001), 8.9% better 1-year survival (90.8% 
vs 81.9%, p=0.004) and 11.6% better 2-year survival 
conditional on 1-year survival (94.1% vs 82.5%, p=0.001) 
compared with non-trial patients (table 2, figure 2). To T
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determine whether the effects of trial recruitment on 
survival were measurable across the age cohort, we anal-
ysed 15–19 year olds and 20–24 year olds separately. The 
differences in survival at all time points remained signif-
icant in the 15–19 year old age group (table 2). Two-year 
and conditional 2-year survival showed a non-significant 
trend to better in trial patients than non-trial patients 
in the 20–24 year old cohort. The results for 2008–2010 
(after closure of UKALLXII) are similar to those for the 
whole study period: 20–24 year olds in the trial had a 
2-year survival 10.2% better than those not in the trial, 
but this did not reach statistical significance p=0.393.
To determine whether the deaths were evenly spaced 
after diagnosis we next analysed the number of deaths in 
trial and non-trial patients by quarter-year from diagnosis. 
Table 3 shows the number and percentage of deaths by trial 
status for each quarter-year and year of follow-up. A total 
of 35 (14.6%) trial patients died in the 2 years following 
diagnosis compared with 86 (32.6%) of non-trial patients 
(p<0.001). The difference in the proportion of deaths 
between trial and non-trial patients was 9% (18.2%–
9.2%; p=0.004); fewer deaths in trial patients during the 
first year and 11.6% (17.6%–6.0%; p<0.001) during the 
second. However, the largest number of deaths overall 
and the largest difference between trial and non-trial 
patients for any quarter was in the first 3 months after 
diagnosis: 6 (2.5%) trial patients died compared with 21 
(8.0%) non-trial patients (p=0.007).
exploratory analysis of trial recruitment by place of care
The data available in national registry records were not 
sufficient to allow us to determine the reasons for non-re-
cruitment of non-trial patients, how non-trial patients 
were treated or the training background of treating physi-
cians (paediatric, TYA or adult). However, we were able 
to compare trial recruitment rates between patients for 
whom an enhanced TYAC cancer registration form had 
been submitted and those with no TYAC form. The trial 
recruitment rates were significantly different between 
the two groups: 73.5% of patients with a submitted TYAC 
form were recruited compared with 51.9% of those for 
whom a form was not submitted (p=0.001, table 4). The 
difference was highest among patients aged 20–24 years 
(61.5% trial recruitment among patients with associated 
TYAC forms versus 36.4% without). Patients for whom 
a TYAC form was submitted had a 2-year survival of 80.8% 
compared with 82.8% for those without a form (p=0.771).
DIsCussIOn
By combining trial and national cancer registry data, 
we have demonstrated a significant survival advantage 
to participation in the most recently completed, large 
prospective clinical trial for TYA patients with ALL, 
which is measurable at a population level. This is the first 
study to have demonstrated such a survival advantage in 
any cancer type in the TYA age group. The difference 
in survival was highly significant, with a 17.9% superior 
survival at 2 years in trial patients compared with non-trial 
patients. The risk of mortality at 2 years in those treated 
outside of the trial was twice that of those on UKALL2003 
(32.6% compared with 14.6%, p<0.001) and was most 
striking during the first 3 months after diagnosis (8.0% 
compared with 2.5%, p=0.007).
This retrospective analysis of the impact of clinical trial 
recruitment on survival was possible because the consent 
process for UKALL2003 included explicit consent for the 
trial data to be shared with regional and national cancer 
registries and because the UK has full population coverage 
for cancer registration. This study, however, did show a 
number of limitations of the cancer registration system 
for England during the period 2004–2010 including (1) 
accuracy of diagnosis: 20 patients on UKALL2003 with a 
diagnosis other than ALL on NCDR and (2) timeliness: 
12 patients on ENCORE but not on NCDR. In addition, 
the main source of diagnostic data for cancer registries 
during the study period was histopathology laborato-
ries, leading to difficulties in obtaining high quality data 
on patients with ALL. There were no data available for 
the well-established prognostic variables in ALL, thus 
precluding comparison of the frequency of different risk 
groups between those treated on or off trial. Data were 
collected by regional registries and then compiled into a 
national database, which took considerable time. PHE has 
made many improvements since taking over the NCRAS a 
few years ago including (1) Moving to a single, completely 
integrated national registry, (2) setting up systems that 
report in real time from a wide variety of sources, such 
as MDTs, leading to more timely and accurate data, (3) 
reviewing access to specialist haematological diagnostic 
datasets to improve the data quality of haematological 
Table 1b Trial participation over time in 15–17 year olds
Year of 
diagnosis Proportion Percentage 95% CI p Value
2004–2007 83/140 59.3 51.0 to 67.1 0.007
2008–2010 66/86 76.7 66.8 to 84.4
Figure 2 Two-year relative survival by age group and trial 
status.
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cancers and (4) producing an analysis database that is 
constantly kept up to date.
We also recognise a number of potential confounding 
variables in this study. Potential confounders which could 
increase the observed difference between those on trial 
compared with those treated off trial include centre 
effect, selection bias and use of a superior protocol and 
those reducing the difference include recruitment to 
other ALL clinical trials.
Any potential benefit to participation of young people 
in clinical trials may be derived from the treating centre 
rather than trial participation itself (centre effect). Centres 
offering clinical trials are often larger, academic institu-
tions, seeing a higher number of patients with a specific 
disease, a larger clinical research infrastructure and a 
more resourced workforce, all of which may contribute 
to a more favourable outcome.16 Over the last 10 years, 
there has been a gradual reconfiguration of services 
providing care for young people aged 16–24 years with 
cancer in the UK; this includes the development of Prin-
cipal Treatment Centres, designation of other hospitals 
offering TYA services closer to the patients’ homes and an 
overview of the holistic care of all patients provided by the 
TYA multidisciplinary team (MDT). Between 2004 and 
2010, these pathways were not fully established, but the 
submission of TYAC enhanced cancer registration forms 
have been used as a surrogate indicator that an individual 
patient received treatment according to regionally agreed 
and commissioned TYA pathways under the supervision 
of the TYA PTC. It is therefore interesting to note that a 
significantly higher proportion of patients recruited onto 
UKALL2003 had been registered centrally via the TYAC 
notification system than non-trial patients (73.5% with a 
TYAC form compared with 51.9% without, p=0.001). This 
was particularly marked in the older age group. However, 
the finding that 2-year survival was not higher in those 
patients with a submitted TYAC form does not support 
the argument that the better survival for those in the trial 
was mainly due to having been managed at larger centres.
While selection bias, in which the highest risk patients 
(eg, those with a very high white count, renal or hepatic 
impairment or large mediastinal mass at presentation) 
could not participate in the trial, may be a confounder 
it is unlikely to have had a significant impact on our 
results as (1) UKALL2003 was a population-based trial 
for which all children and young people with ALL were 
eligible, irrespective of severity or risk group at presenta-
tion and (2) it also permitted recruitment within 7 days of 
commencement of chemotherapy. Patients with Philadel-
phia chromosome positive (Ph +ve) ALL were ineligible 
for UKALL2003, but Ph +ve patients were included in the 
non-trial arm, as NCDR did not include details of Ph chro-
mosome status. The presence of the Philadelphia chro-
mosome in ALL confers a poorer prognosis25 and could 
therefore increase the survival difference observed in this 
study. However, we feel that this is unlikely to have been a 
Table 2 One and 2-year survival by age group and trial status
Trial status Age group Number of patients Deaths Survival (%) 95% CI p Value
One-year survival
Trial 15–19 203 17 91.7 86.9 to 94.7 <0.001
Non-trial 134 30 77.6 69.6 to 83.8
Trial 20–24 36 5 86.2 69.8 to 94.0 0.969
Non-trial 130 18 86.2 79.0 to 91.1
Trial 15–24 239 22 90.8 86.4 to 93.9 0.004
Non-trial 264 48 81.9 76.6 to 86.0
2 year conditional on 1-year survival
Trial 15–19 186 10 94.7 90.3 to 97.1 0.008
Non-trial 104 16 84.7 76.2 to 90.4
Trial 20–24 31 3 90.4 73.0 to 96.9 0.236
Non-trial 112 22 80.4 71.8 to 86.7
Trial 15–24 217 13 94.1 90.0 to 96.6 0.001
Non-trial 216 38 82.5 76.7 to 87.0
Two-year survival
Trial 15–19 203 27 86.8 81.3 to 90.7 <0.001
Non-trial 134 46 65.7 57.0 to 73.1
Trial 20–24 36 8 77.9 60.5 to 88.3 0.381
Non-trial 130 40 69.3 60.6 to 76.5
Trial 15–24 239 35 85.4 80.3 to 89.3 <0.001
Non-trial 264 86 67.5 61.5 to 72.8
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significant confounding variable since the prevalence of 
Ph +ve ALL in UKALL2003 overall was only 1.8% and the 
observed difference between groups was non-significant 
in the older patients despite the frequency of the Phila-
delphia chromosome increasing with increasing age.
During the study period, TYA patients with Ph +ve disease 
were eligible for the ESPHALL or UKALLXII (until 2006) 
trials, depending on age, and older patients with Ph −ve 
disease were eligible for recruitment onto UKALLXII 
(lower age limit 18th birthday from 2004, 20th birthday 
from 2006 and 25th birthday from 2007). While we do 
not know the proportions of non-UKALL2003 patients 
recruited to these trials, if trial participation in itself 
confers a survival advantage, recruitment of patients to 
these other clinical trials would be expected to reduce 
observed differences between our two study groups, 
reduce any residual confounding from the exclusion 
of Ph +ve patients from UKALL2003 and may have also 
contributed to the non-significant difference in survival 
between trial and non-trial patients aged 20–24 years. This 
is further supported by the observation that only three 
UK patients aged 15–17 years were recruited to ESPHALL 
(Ph +ve ALL only), but 100 patients aged 16–24 years 
were recruited to UKALLXII (Ph +ve and –ve ALL). The 
relative contribution of treatment protocol on outcome 
differences was impossible to assess in this study, since the 
registry dataset did not include which specific regimen 
was used.
Recruitment to clinical trials in TYA patients with 
cancer is poor due to a range of factors including lack 
of an available trial, heterogenous referral pathways, 
differences in treating centres as well as lack of desire 
to participate by this age group.4 9 13 26 Overall, approxi-
mately 50% of TYA patients in England with ALL partici-
pated in UKALL2003. Although this figure is lower than 
the proportion of younger children who participated in 
the trial, it compares favourably to other cancer trials 
reported in this age group; in the UK between 2005 and 
2010, only 850 of 2860 patients aged 15–19 years (30%)
and 562 of 4011 patients aged 20–24 years (14%) were 
recruited to a clinical trial.4 Encouragingly, recruit-
ment to UKALL2003 improved over time. In part, this 
was expected in the group aged 18–24 years, given the 
sequential increase in age eligibility criteria over time. 
However, even in the patients aged 15–17 years who were 
eligible for participation throughout the study period, 
participation increased from 59.3% in 2004–2007 to 
76.7% in 2008–2010 (p=0.007). Despite this, there were 
still a substantial number of young people who did not 
participate, particularly among 20–24 year olds, where 
participation was only 45.1%. Fern et al propose that 
there are five factors (five ‘A’s’) important in improving 
TYA cancer trial recruitment; available, accessible, aware, 
appropriate and acceptable. The relatively high level of 
recruitment of TYA patients with ALL to UKALL2003 and 
its improvement over time probably reflects an increasing 
awareness (as a result of newsletters and the trial coordi-
nators presenting at a series of national meetings) and T
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acceptability among paediatric and adult haematologists 
that UKALL2003 offered an effective (ie, appropriate) 
treatment strategy, with increasing availability and accessi-
bility as the age range was increased and a greater number 
of adult centres opened the trial.
In conclusion, we report a specific survival advantage 
to participation in the UKALL2003 trial for TYA patients 
with ALL. This is the first study to have demonstrated a 
survival advantage of trial participation in TYA patients 
with any cancer and suggests a benefit to an individual 
patient in taking part. These data highlight the impor-
tance of national and international efforts to (1) improve 
recruitment of TYA patients with cancer to clinical trials, 
(2) configure TYA cancer services to provide young 
people with access to appropriate trials and the opportu-
nity to participate and (3) the need to continue to collect 
accurate treatment and outcome data at a population 
level to allow evaluation of treatment in patients who have 
not accessed clinical trials. In England, these duties are 
the responsibilities, respectively, of the National Cancer 
Research Institute, NHS England and PHE, working 
together towards the goal of best patient outcomes. The 
data we present suggest that significant improvements 
in the delivery of appropriate cancer treatment are still 
much needed for this vulnerable young population.
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